Published online Sep 6, 2023. doi: 10.12998/wjcc.v11.i25.5878
Peer-review started: July 12, 2023
First decision: August 2, 2023
Revised: August 7, 2023
Accepted: August 11, 2023
Article in press: August 11, 2023
Published online: September 6, 2023
Processing time: 51 Days and 5.4 Hours
Acute respiratory distress syndrome (ARDS) precipitates is widespread pulmonary injury in impacted individuals, the neonatal respiratory distress syndrome (NRDS), primarily observed in preterm infants, represents a prevalent critical condition in neonatal clinical settings.
Presently, respiratory ailments such as NRDS, congenital diaphragmatic hernia, and meconium aspiration syndrome can be effectively managed with high-frequency oscillatory ventilation (HFOV) combined with pulmonary surfactant (PS) (HFOV+PS) inhalation therapy in neonates and infants. However, additional investigations are required to elucidate the impacts of the HFOV and PS combination on ARDS.
The aim of this study is to investigate the clinical efficacy of various ventilation strategies combined with PS therapy in the treatment of NRDS.
A total of 20 neonates diagnosed with RDS, admitted between May 2021 and June 2022, were randomly assigned to either a research group or a control group. Neonates in the research group received treatment involving HFOV in conjunction with PS. In contrast, neonates in the control group were administered either controlled mechanical ventilation (CMV) or synchronous intermittent mandatory ventilation, combined with PS.
From 6-48 h post-treatment, both groups demonstrated significant improvements in arterial blood pH and oxygen partial pressure, along with a significant decrease in carbon dioxide partial pressure compared to pre-treatment values (P < 0.05). Although these changes progressed over time, there were no significant differences between the two groups (P > 0.05). However, the research group had significantly lower X-ray scores, shorter hospitalization time, and less time on O2 therapy compared to the control group (P < 0.05). Mortality rates were similar between the two groups (P > 0.05), but the research group had a significantly lower incidence of complications (P < 0.05).
Our findings suggest that for infants with ARDS, the utilization of HFOV in conjunction with PS demonstrates a significant advantage over the use of CMV with PS. Specifically, the HFOV+PS approach notably reduces both the duration of hospitalization and the necessity for prolonged mechanical ventilation. Importantly, these benefits are achieved without any attendant increase in the incidence of complications. This evidence provides a compelling case for the preferential use of HFOV+PS in the management of infant ARDS, to optimize patient outcomes and enhance the efficiency of care.
Our future research will be based on alleviating the economic pressure of patients and finding the cheapest treatment to treat Infant respiratory distress syndrome.